June 25, 2015 2 3 4 ` FY10 FY11 FY12 FY13 FY14 FY15 Gross - PowerPoint PPT Presentation

June 25, 2015

2

3

4

` FY10 FY11 FY12 FY13 FY14 FY15 Gross Revenue( ` mn) 7,207 2,008 9,215 44 11 55 20,265 26,054 31,475 37,687 43,842 51,785 (3) Gross Revenue($ mn) 322 414 500 598 696 822 14 6 YoY Growth 25.50% 28.60% 20.80% 19.70% 16.30% 18.12% EBITDA 3,013 4,190 5,131 6,082 6,724 7,347 64% EBITDA Margin 14.90% 16.10% 16.30% 16.10% 15.30% 14.19% Profit After Tax (PAT) 1,376 1,839 2,194 3,044 3,168 3,399 PAT Margin 6.80% 7.10% 7.00% 8.10% 7.20% 6.56% 6,200+ 10,000+ 3,400+ Net Worth 16,776 19,238 25,194 27,641 29,955 32,443 Total Loans 9,132 9,585 8,183 12,179 13,601 20,142 Cash and Cash 3,117 2,664 3,588 6,842 4,151 4,833 Equivalents (2) All financial are for fiscal year (FY) ended March 31. (3) Fx used: US$1= ` 63. across 21 states FY15 at Apollo Hospitals* 34% 1,822 350,000+ 250,000 3,200,000+ Admissions Preventive Health Out-Patients Checks 11,000+ 5,000+ 14,000+  Health Insurance (AHEL stake 10.2%) Heart Joint Neuro Surgical  Surgeries Replacements Operations Primary Clinics  Sugar Clinics 500 1,100+ 400+ 2%  Birthing centres – “CRADLE” Robotic Kidney Liver  Day Care Centres Surgeries Transplants Transplants 155,000+  Shareholding (1) : Promoters (34.4%), FIIs & FCBs (55.6%), MF/FI/IC (2.0%), 120 170 Radiotherapy Others (8.0%) Sessions Countries Bone Marrow Market capitalization of ` 190,490 mn (4) and Debt to Equity ratio of 0.52x (1)  47,000+ Medical Value Transplants Travel Chemotherapy As on 31 st Mar 2015. Sittings (1) (4) NSE Closing price on 31 st Mar 2015 # Source: Frost & Sullivan * FY15 info for owned hospitals only. Does not include managed hospitals Source: Company audited financials and Q4FY15 Earnings Update. 5

Capacity Beds Operational No. of Hospitals Category Wise Owned 7,207 6,321 44 * Managed 2,008 2,008 11 Grand Total 9,215 8,329 55 # of Beds: 9,215 # of Beds: 5,100 Cluster Wise (Owned) # of Hospitals: 55 # of Hospitals: 54 Chennai 1,718 1,495 13 Hyderabad 959 930 7 Kolkata 540 540 2 Delhi 875 713 2 Bangalore 499 378 2 # of Beds: 2,078 Ahmedabad 320 274 2 # of Hospitals: 15 Tamilnadu 808 589 4 (outside Chennai) Bhubaneswar 290 264 1 Other India 1,198 1,138 11 # of Beds: 7,452 Grand Total 7,207 6,321 44 # of Hospitals: 29 Maturity Wise (Owned) > 5 years 4,406 4,334 24 3 - 5 years 957 773 7 1 - 3 years 1,136 740 6 < 1 year 708 474 7 # of Beds: 5,118 Grand Total 7,207 6,321 44 # of Hospitals: 15 Owned Beds CAGR (FY05-15) # of Beds: 1,103 # of Beds: 2,016 # of Beds: 1,250 9.2% # of Hospitals: 7 # of Hospitals: 10 # of Hospitals: 1 # Beds as on 31 st March 2015. Source: Company Reports, CRISIL Research * Fortis corporate presentation as of April 2015, publicly available on Fortis Healthcare Ltd.’s website. Source: Company MIS Reports, 6

7

2011-2015 2011 Apollo Day Care Surgery — facility for minor surgeries requiring short stay. Hospital at Karaikudi, Tamil Nadu 2013 Hospitals in Vanagaram (Chennai), Jayanagar (Bengaluru) & Trichy 2015 Hospitals in Nashik, Nellore, Women & child centers at Karapakkam & SMR, OMR Perungudi 2011 Apollo Institute of Robotic Surgery launched - the first robotic centre in Tamil Nadu 2012 Placed order for Proton therapy equipment for Cancer treatment 2013 Apollo Health City, Hyderabad performs Minimally Invasive Knee Replacement (Resurface) Surgery using OrthoGlide Medial Knee system 9,215 beds FY 1,822 stores 2015 Revenues 51,785 mn. 8

9

10

In order to meet the global median of 30 beds per 10,000 population, India will need to invest over ` 14 trillion ($230 bn) Source: CRISIL Research 11

12

13

14

15

Human Sigma • 1 st in India to adopt Human Sigma by Guest Relation mapping customer and employee • Apollo has adopted the engagement engagement to the Gallup “S” Pathway for Voice of Customer (VOC) Methodology • Partnered with Gallup to benchmark • Ranked this year among top 37 e-customer feedback with best in class companies that partner with Gallup hospitals globally • This recognises exceptional leadership • In-house framework captures VOC that understands that engaging from Interactions and converts them employees drives real business into Qualitative and quantitative outcomes feedback for quick follow-up action • Apollo now among globally recognised • Awarded “Best Innovation in service organisation for mastering how to engage delivery” In 2013 by AIMA & Hospitals workforce to deliver sustainable growth Management Awards Admissions • Minimises waiting Service time for planned admissions • Dedicated rooming Excellence experience that orients patients and attendees to Tender Loving Care various hospitals • Core training module for all services nurses • Inspires the conversion of daily interactions into memorable experiences, resulting in enhanced courtesy index for nursing Discharge • Tender Loving Care (TLC) - • Post-discharge calls to patients for Training for frontline staff suggestions and feedback 72 • TLC acknowledge as “Best hours after discharge Training Initiative in Healthcare” • Speedy discharge summary for at “Asian Learning & planned discharges Development Leadership Awards” In Dubai in 2013 16

17

 Healthcare services: Improvement in operating metrics  Strong continued revenue growth in mature clusters  New Hospitals – driving substantial revenue growth – through quick ramp up  Standalone Pharmacies: Revenue growth and margin improvement  Standalone pharmacies reported a positive EBITDA for each of the last five years FY11, FY12, FY13, FY14 & FY15  All stores are in the growth phase with relatively mature stores growing at a consistent rate with increasing EBITDA margins – improvement in first year store performance due to better ramp-up and lower losses 18 18

19

20

India’s largest organized pharmacy retail chain with a network of 1,822 stores.  Asset light business model with an established track record  Presence in metro centers such as Hyderabad, Chennai, Bengaluru, Pune, Ahmedabad and NCR regions  Offers a wide range of medicines and surgical products, hospital consumables and over-the-counter products  Own brand private labels (FMCG & OTC drugs) constitutes over 6% of FY14 turnover. Target to increase to 20% in next 5 years  Introduced generic and in-house brands (Private Labels)  Consistent growth in standalone pharmacy revenue  Calibrated rollout: 190 stores opened in FY15, 129 stores opened in FY14, 139 stores opened in FY13, 165 stores opened in FY12, 150 in FY11 and 166 in FY10  Increased penetration of private label sales  Integrate supply chain network and optimize inventory levels  Emphasis on margin improvement  Mature cohort of pre-2008 stores have achieved 5.9% EBITDA margins in FY15  Positive overall EBITDA margin FY 11 , FY 12, FY13, FY14 & FY15  Regulatory Update: In September 2012, the Central Government approved the DIPP proposal to permit 51% FDI in multi-brand retail, subject to certain conditions 21